These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16462581

  • 1. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.
    Gupta AA, Capra M, Papaioannou V, Hall G, Maze R, Dix D, Weitzman S.
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):91-4. PubMed ID: 16462581
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin: continuous versus bolus.
    Gratton MA, Smyth BJ.
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):60-1. PubMed ID: 16462573
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [Abstract] [Full Text] [Related]

  • 5. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA, Children's Oncology Group.
    Cancer; 2005 Aug 15; 104(4):841-7. PubMed ID: 15999362
    [Abstract] [Full Text] [Related]

  • 6. Cisplatinum ototoxicity in children, long-term follow up.
    Al-Khatib T, Cohen N, Carret AS, Daniel S.
    Int J Pediatr Otorhinolaryngol; 2010 Aug 15; 74(8):913-9. PubMed ID: 20846503
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
    Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A.
    Acta Otorhinolaryngol Ital; 2002 Feb 15; 22(1):14-8. PubMed ID: 12236007
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP, Pediatric Oncology Group 9049, Children's Cancer Group 8882.
    J Clin Oncol; 2004 Jul 01; 22(13):2691-700. PubMed ID: 15226336
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.
    Med Pediatr Oncol; 1996 Feb 01; 26(2):95-100. PubMed ID: 8531860
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3759-65. PubMed ID: 17704425
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
    Li Y, Womer RB, Silber JH.
    Eur J Cancer; 2004 Nov 20; 40(16):2445-51. PubMed ID: 15519518
    [Abstract] [Full Text] [Related]

  • 20. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin.
    Sivaprakasam P, Gupta AA, Greenberg ML, Capra M, Nathan PC.
    J Pediatr Hematol Oncol; 2011 Aug 20; 33(6):e226-30. PubMed ID: 21792028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.